T-Cell Therapy Gets Orphan Drug Designation for Pancreatic Cancer

Article

The T-cell therapy targets 6 tumor-associated antigens that are highly expressed in pancreatic cancer.

This content originally appeared on our sister site, OncLive.

The FDA has granted orphan drug designation to the multitumor-associated antigen-specific T-cell therapy (MultiTAA), MT-601, for the treatment of patients with pancreatic cancer.1

MT-601 consists of MultiTAA technology that uses a non-genetically modified cell therapy approach that selectively expands tumor-specific T cells in the blood that can identify a wide range of tumor antigens.2 MT-601 is designed to target 6 tumor-associated antigens highly expressed in pancreatic cancer: PRAME, NY-ESO-1, Survivin, MAGE-A4, SSX2, and WT1.

According to Marker Therapeutics, Inc., this technology differs from other cell therapies that are genetically engineered to identify a single portion of a sing tumor-associated antigen; these T cells can recognize up to 5 antigens to produce a strong, durable antitumor response. These therapies have demonstrated consistent epitope spreading, which induces the T cells within a patient to expand, resulting in a durable effect.

Moreover, the MultiTAA-specific T-cell therapies are based on the selective expansion of a the natural T cells in a patient and are not genetically engineered, thus, they do not carry the risk of mutagenesis and they have been hypothesized to have reduced toxicity vs other CAR T-cell therapies and T-cell receptor–based therapies in the field.

READ MORE: Trial Initiated for Pediatric Liver Cancer Cell Therapy

Data from early clinical trials have indicated that the multi-antigen approach is well tolerated and results in enhanced tumor-killing capability.

“The FDA’s orphan drug designation underscores MT-601’s potential has a treatment for pancreatic cancer, a cancer typically diagnosed at an incurable advanced stage with a total overall 5-year survival rate of 10%,” Peter L. Hoang, president and chief executive officer of Marker Therapeutics, stated in a press release. “Our novel therapy has shown encouraging results in an ongoing phase 1 trial sponsored by Marker’s partners at the Baylor College of Medicine…our therapy has demonstrated the potential to safely produce durable responses in combination with chemotherapy as a first-line treatment option for patients with advanced or metastatic pancreatic adenocarcinoma.”

Data from the phase 1 trial (NCT03192462) were reported during the 2020 ASCO Virtual Scientific Program.2 Thirteen patients received up to 6 monthly infusions of 1 x 107 multiTAA-T cells/m2 in conjunction with ongoing frontline chemotherapy, and without prior protocol-associated lymphodepletion. For 12 of these patients, sufficient cells were generated for all 6 planned doses and 2 doses were available for the remaining patient.

Results showed that while on study treatment, 10 patients had ongoing radiographic stable disease or tumor responses that lasted for 6 months to 19 months; this included 1 radiographic complete response. One patient experienced a mixed response to treatment and 2 experience

progressive disease. Moreover, 9 of the 13 patients had disease control that lasted for longer than the expected duration vs historical controls.

Five additional patients underwent procurement for T-cell product creation but did not receive cells and thus, were not included in the response evaluation. Two of these patients had an unacceptable number of doses of T cells created, 1 had disease progression and initiated a second line of chemotherapy before study enrollment, and 2 had disease progression and died from their disease before enrollment.

“These results also revealed that epitope spreading was consistent in responders to Multi-TAA–specific T cells,” Hoang added in the release.

The initiation of a multicenter phase 1 study that will further examine MT-601 in combination with chemotherapy in the frontline treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer is planned. The study was designed to comprise an initial antigen escalation period that will be followed by a dose-escalation period. The trial is slated to enroll 20 to 25 participants.

Additionally, Marker Therapeutics shared plans to file an investigational new drug application for MT-601 for the treatment of pancreatic cancer later this year.

References
1.Marker Therapeutics receives FDA orphan drug designation for its multi-antigen targeted T cell therapy for pancreatic cancer. News release. Marker Therapeutics, Inc.; January 19, 2022. Accessed January 20, 2022. https://bit.ly/33SNmh5
2. Smaglo BG, Musher BL, Vasileiou S, et al. A phase I trial targeting advanced or metastatic pancreatic cancer using a combination of standard chemotherapy and adoptively transferred nonengineered, multiantigen specific T cells in the first-line setting (TACTOPS). J Clin Oncol. 2020;38(suppl 15):4622. doi:10.1200/JCO.2020.38.15_suppl.4622
Related Videos
Alexandra Gomez-Arteaga, MD
Pietro Genovese, PhD, the principal investigator at the Gene Therapy Program of Dana-Farber/Boston Children’s Cancer and Blood Disorder Center
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
John DiPersio, MD, PhD, the director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine
Aude Chapuis, MD, an associate professor in the Translational Science and Therapeutics Division at Fred Hutch Cancer Center
Amar Kelkar, MD, a stem cell transplantation physician at the Dana-Farber Cancer Institute
David Porter, MD
N. Nora Bennani, MD
Rebecca Epperly, MD, a clinical investigator in the Department of Bone Marrow Transplantation & Cellular Therapy at St. Jude Children’s Research Hospital
© 2024 MJH Life Sciences

All rights reserved.